AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26542030 — intervention group
Group type: COMPARATOR
Intervention: BSC
Number of subjects: 98
Study 26542030 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment
Number of subjects: 98
Study 24131072 — intervention group
Group type: EXPERIMENTAL
Intervention: 1550-nm fractional laser
Number of subjects: 12
Study 24131072 — intervention group
Group type: COMPARATOR
Intervention: 595-nm pulsed dye laser (PDL)
Number of subjects: 12
Study 22925988 — intervention group
Group type: EXPERIMENTAL
Intervention: S(‐)‐amlodipine nicotinate 2.5 to 5 mg once daily
Number of subjects: 38
Study 22925988 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate 5 to 10 mg once daily
Number of subjects: 38
Study 20174731 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial intervention (TRI)
Number of subjects: 200
Study 20174731 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral intervention (TFI)
Number of subjects: 200
Study 18343607 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG)
Number of subjects: 19
Study 18343607 — intervention group
Group type: COMPARATOR
Intervention: Curriculum-and-instruction program directed at reading achievement
Number of subjects: 19
Study 18343607 — intervention group
Group type: COMPARATOR
Intervention: Standard program
Number of subjects: 19
Study 16264208 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiot PTFE-covered stent
Number of subjects: 30
Study 16264208 — intervention group
Group type: COMPARATOR
Intervention: Conventional bare-metal stent
Number of subjects: 30
Study 12743773 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with lansoprazole (LPZ), amoxicillin (AMPC), and clarithromycin (CAM) for 7 days
Number of subjects: 0
Study 9578254 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 1 ml (10 mg) injected into the superior compartment of the temporomandibular joint
Number of subjects: 15
Study 8087958 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct thrombin inhibitors
Number of subjects: 0
Study 8087958 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 2753406 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g lactulose (L)
Number of subjects: 8
Study 2753406 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g lactulose (L) with 20 mg metoclopramide (M)
Number of subjects: 8
Study 2753406 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g lactulose (L)
Number of subjects: 8
Study 2753406 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g lactulose (L) with 7.5 mg diphenoxylate (D)
Number of subjects: 8
Study 795363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 10
Study 795363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 795363 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 10
Study 30376089 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine (OPV) shedding
Number of subjects: 3
Study 26883899 — intervention group
Group type: EXPERIMENTAL
Intervention: nMARQ® catheter
Number of subjects: 35
Study 26883899 — intervention group
Group type: COMPARATOR
Intervention: Single-tip ablation catheter with circular mapping catheter
Number of subjects: 35
Study 25160673 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 of 12% and 4‐hour cycling
Number of subjects: 12
Study 25160673 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2=21% and 4‐hour cycling
Number of subjects: 12
Study 25160673 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2=8.5% to 12% at rest
Number of subjects: 12
Study 25160673 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2=12% and 4‐hour cycling
Number of subjects: 12
Study 25160673 — intervention group
Group type: COMPARATOR
Intervention: Control (normoxia)
Number of subjects: 12
Study 23204152 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 11
Study 23204152 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine in water
Number of subjects: 11
Study 23204152 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 11
Study 23204152 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 11
Study 20354383 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered cultural competence training
Number of subjects: 57
Study 20354383 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 57
Study 18599016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 13-cis-retinoic acid (RA) 10 mg twice daily for eight weeks
Number of subjects: 35
Study 18599016 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RA)
Number of subjects: 35
Study 16000666 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal interference screws
Number of subjects: 41
Study 16000666 — intervention group
Group type: COMPARATOR
Intervention: Bioabsorbable poly-l-lactic acid screws
Number of subjects: 41
Study 12449148 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with Bonin (Disodium Pamidronate)
Number of subjects: 34
Study 12449148 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 34
Study 10091407 — intervention group
Group type: EXPERIMENTAL
Intervention: TAL1 gene rearrangement
Number of subjects: 17
Study 10091407 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of heterozygosity (LOH)
Number of subjects: 17
Study 10091407 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite instability (MI)
Number of subjects: 17
Study 10091407 — intervention group
Group type: COMPARATOR
Intervention: TAL1 gene involvement, LOH, or MI at 1p32
Number of subjects: 17
Study 8785026 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure (2,000 lux) from 2.00 to 4.00 h
Number of subjects: 6
Study 8785026 — intervention group
Group type: COMPARATOR
Intervention: Dark condition (resting supine in bed from 21.00 to 7.00 h)
Number of subjects: 6
Study 2294875 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative fluorometry with intravenous fluorescein administration before amputation
Number of subjects: 56
Study 2294875 — intervention group
Group type: COMPARATOR
Intervention: Clinical judgment
Number of subjects: 56
Study 2294875 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative fluorometry
Number of subjects: 56
Study 76750 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple mastectomy and postoperative radiotherapy
Number of subjects: 1020
Study 76750 — intervention group
Group type: COMPARATOR
Intervention: Simple mastectomy alone
Number of subjects: 1020
Study 76750 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy alone
Number of subjects: 1020
Study 6226527 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-DPD
Number of subjects: 257
Study 6226527 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-MDP 1
Number of subjects: 257
Study 6226527 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-MDP 2
Number of subjects: 257
Study 31229501 — intervention group
Group type: EXPERIMENTAL
Intervention: BIVV009 (sutimlimab), 60 mg/kg infusions, 4 weekly doses
Number of subjects: 10
Study 31229501 — intervention group
Group type: EXPERIMENTAL
Intervention: BIVV009 (sutimlimab)
Number of subjects: 10
Study 28410921 — intervention group
Group type: EXPERIMENTAL
Intervention: MSPrebiotic®
Number of subjects: 84
Study 28410921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 26871828 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching assistants majored in the liberal arts (TAF)
Number of subjects: 123
Study 26871828 — intervention group
Group type: COMPARATOR
Intervention: Attending physicians (APF)
Number of subjects: 123
Study 26871828 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical medicine-unrelated topics
Number of subjects: 123
Study 26871828 — intervention group
Group type: COMPARATOR
Intervention: Clinical medicine-related topics
Number of subjects: 123
Study 25015649 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (Se) during radiation therapy
Number of subjects: 81
Study 25015649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no selenium supplementation)
Number of subjects: 81
Study 22549948 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction diet (goal of 10% weight loss, N = 118)
Number of subjects: 439
Study 22549948 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + exercise (N = 117)
Number of subjects: 439
Study 22549948 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (225 min/wk of moderate‐to‐vigorous activity, N = 117)
Number of subjects: 439
Study 22549948 — intervention group
Group type: COMPARATOR
Intervention: Control (N = 87)
Number of subjects: 439
Study 20809953 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring using the Intel Health Guide device
Number of subjects: 200
Study 20809953 — intervention group
Group type: COMPARATOR
Intervention: Usual care (appointments as problems arise and 24-hour nurse line support)
Number of subjects: 200
Study 17939262 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg IV q24h followed by 500 mg orally q24h
Number of subjects: 50
Study 17939262 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 500 mg/100 mg IV q8h with oral clarithromycin 500 mg q12h, then oral amoxicillin/clavulanate 250 mg/125 mg q8h with oral clarithromycin 500 mg q12h
Number of subjects: 50
Study 15998164 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid abusers
Number of subjects: 740
Study 15998164 — intervention group
Group type: COMPARATOR
Intervention: Nonabusers
Number of subjects: 740
Study 11973187 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 2000 mg and Celecoxib 200 mg
Number of subjects: 112
Study 11973187 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg
Number of subjects: 112
Study 11973187 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 2000 mg
Number of subjects: 112
Study 11973187 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Vitamin C, 500 mg)
Number of subjects: 112
Study 9805728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (specific intervention details not provided)
Number of subjects: 0
Study 9805728 — intervention group
Group type: COMPARATOR
Intervention: Control arm (specific control details not provided)
Number of subjects: 0
Study 7859695 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaghetti without paracetamol
Number of subjects: 8
Study 7859695 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaghetti containing 1.5 g paracetamol
Number of subjects: 8
Study 7859695 — intervention group
Group type: COMPARATOR
Intervention: Mashed potatoes with 1.5 g paracetamol
Number of subjects: 8
Study 2808056 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging lymphadenectomy (SL)
Number of subjects: 445
Study 2808056 — intervention group
Group type: COMPARATOR
Intervention: Lymphangiography (LAG)
Number of subjects: 445
Study 2808056 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (prostate vs. prostate and pelvic lymph nodes)
Number of subjects: 445
Study 1020682 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexetimide (0.5 to 1.5 mg daily)
Number of subjects: 69
Study 1020682 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment with antiparkinsonian agents)
Number of subjects: 69
Study 30663606 — intervention group
Group type: EXPERIMENTAL
Intervention: CVT-301 84 mg
Number of subjects: 351
Study 30663606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 27847124 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive robotic‐assisted hand motion using the Gloreha device, twice a day for 2 weeks
Number of subjects: 35
Study 27847124 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (control group)
Number of subjects: 35
Study 25890874 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins E (α‐[600 mg RRR‐α‐tocopherol, αT] and γ‐[600 mg of RRR‐γT]) and C (1000 mg ascorbic acid, AA)
Number of subjects: 29
Study 25890874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 24360178 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Channel Blocker (CCB)
Number of subjects: 531
Study 24360178 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II Receptor Antagonist (ARB)
Number of subjects: 531
Study 24360178 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB + ARB
Number of subjects: 531
Study 24360178 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled blood pressure
Number of subjects: 531
Study 24360178 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled blood pressure
Number of subjects: 531
Study 21900784 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg daily)
Number of subjects: 542
Study 21900784 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg daily)
Number of subjects: 542
Study 19912686 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg per day
Number of subjects: 0
Study 19912686 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (LMV) 100 mg per day
Number of subjects: 0
Study 17243057 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated IFN-alpha-2b (1.0 micro g/kg)
Number of subjects: 230
Study 17243057 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha-2b (3 MIU)
Number of subjects: 230
Study 15499535 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical GM-CSF (1-2 microg/cm2/lesion, applied 3 times weekly for 3 weeks)
Number of subjects: 20
Study 15499535 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, applied 3 times weekly for 3 weeks)
Number of subjects: 20
Study 10806591 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms of triptorelin
Number of subjects: 30
Study 10806591 — intervention group
Group type: COMPARATOR
Intervention: 100 micrograms of triptorelin
Number of subjects: 30
Study 8840994 — intervention group
Group type: EXPERIMENTAL
Intervention: G9-209 peptide (ITDQVPFSY)
Number of subjects: 13
Study 8840994 — intervention group
Group type: EXPERIMENTAL
Intervention: G9-280 peptide (YLEPGPVTA)
Number of subjects: 13
Study 8840994 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified peptides (G9-209/2M and G9-280/9V)
Number of subjects: 13
Study 1462421 — intervention group
Group type: EXPERIMENTAL
Intervention: Andion
Number of subjects: 52
Study 1462421 — intervention group
Group type: COMPARATOR
Intervention: Becotide
Number of subjects: 52
Study 6152280 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg b.i.d.
Number of subjects: 30
Study 6152280 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg b.i.d.
Number of subjects: 30
Study 6152280 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 30
Study 31416897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 4901
Study 28802777 — intervention group
Group type: EXPERIMENTAL
Intervention: LIA with liposomal bupivacaine (LB) 266 mg/20 mL (admixed with bupivacaine HCl 0.5%, 20 mL)
Number of subjects: 140
Study 28802777 — intervention group
Group type: COMPARATOR
Intervention: LIA with bupivacaine HCl 0.5%, 20 mL
Number of subjects: 140
Study 28802777 — intervention group
Group type: EXPERIMENTAL
Intervention: LIA with liposomal bupivacaine (LB)
Number of subjects: 140
Study 27502855 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive patient support tool (active group)
Number of subjects: 174
Study 27502855 — intervention group
Group type: COMPARATOR
Intervention: Simplified tool (control group)
Number of subjects: 174
Study 25713053 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood withdrawal (Group 1)
Number of subjects: 104
Study 25713053 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood withdrawal with blood loss sequestration (Group 2)
Number of subjects: 104
Study 25713053 — intervention group
Group type: COMPARATOR
Intervention: Control group (no autologous blood withdrawal)
Number of subjects: 104
Study 22951019 — intervention group
Group type: EXPERIMENTAL
Intervention: ACD/Ca(plus)/lactate
Number of subjects: 81
Study 22951019 — intervention group
Group type: EXPERIMENTAL
Intervention: TSC/Ca(min)/bicarbonate
Number of subjects: 81
Study 22951019 — intervention group
Group type: COMPARATOR
Intervention: Hep/lactate
Number of subjects: 81
Study 21139879 — intervention group
Group type: EXPERIMENTAL
Intervention: New pictorial warnings
Number of subjects: 140
Study 21139879 — intervention group
Group type: COMPARATOR
Intervention: Old text‐only warnings
Number of subjects: 140
Study 18459999 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimization of mycophenolate mofetil (MMF) early (30 d) after renal transplantation
Number of subjects: 124
Study 18459999 — intervention group
Group type: COMPARATOR
Intervention: Minimization of mycophenolate mofetil (MMF) late (90 d) after renal transplantation
Number of subjects: 124
Study 18459999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus with concomitant use of diltiazem
Number of subjects: 124
Study 18459999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus concentrations (trough > 10 ng/mL) in the first seven days after transplant
Number of subjects: 124
Study 16905960 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 7
Study 16905960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 14551015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 349
Study 14551015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 349
Study 14551015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 10992756 — intervention group
Group type: EXPERIMENTAL
Intervention: Health consultation with a practice nurse
Number of subjects: 132
Study 10992756 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 132
Study 8864793 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (30 g, 150 ml, 15 min)
Number of subjects: 21
Study 8864793 — intervention group
Group type: COMPARATOR
Intervention: Placebo (150 ml NaCl)
Number of subjects: 21
Study 8864793 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (in PPH patients)
Number of subjects: 21
Study 1625490 — intervention group
Group type: COMPARATOR
Intervention: Rubidazone
Number of subjects: 611
Study 1625490 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 611
Study 1625490 — intervention group
Group type: EXPERIMENTAL
Intervention: Late intensification with POMP (mercaptopurine + vincristine + methotrexate + prednisone)
Number of subjects: 611
Study 1625490 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 611
Study 1625490 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic intrathecal therapy with cytosine arabinoside
Number of subjects: 611
Study 1625490 — intervention group
Group type: COMPARATOR
Intervention: Maintenance with OAP (vincristine + cytosine arabinoside + prednisone)
Number of subjects: 611
Study 6747940 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-access physiotherapy
Number of subjects: 0
Study 6747940 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard referral)
Number of subjects: 0
Study 31345710 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 140
Study 30282171 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cosmetic incision with intradermal suture using 6-0 absorbable Vicryl stitches and Dermabond skin adhesive
Number of subjects: 42
Study 30282171 — intervention group
Group type: COMPARATOR
Intervention: Traditional S shaped incision with continuous suture using 4-0 Prolene stitches
Number of subjects: 42
Study 27012596 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine Patch (9.5 mg/24 h)
Number of subjects: 501
Study 27012596 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine Capsule (6 mg Twice Daily)
Number of subjects: 501
Study 25423958 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeper Sv radiation monitor (real-time operator dose reporting through auditory feedback)
Number of subjects: 505
Study 25423958 — intervention group
Group type: COMPARATOR
Intervention: No use of Bleeper Sv radiation monitor (control group)
Number of subjects: 505
Study 22781456 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured triglycerides in Group A (n = 10)
Number of subjects: 20
Study 22781456 — intervention group
Group type: COMPARATOR
Intervention: MCT/LCT in Group B (n = 10)
Number of subjects: 20
Study 19732126 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (Dipeptiven, Fresenius) as continuous infusion for 6 hours at 0.5 g/kg for 3 days prior to, and 7 days following surgery
Number of subjects: 55
Study 19732126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 19732126 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (Dipeptiven, Fresenius)
Number of subjects: 55
Study 18729297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) intervention, n = 15, received 9 bi-weekly 1-hour individual sessions.
Number of subjects: 27
Study 18729297 — intervention group
Group type: COMPARATOR
Intervention: Control condition, n = 12.
Number of subjects: 27
Study 15937879 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied during maximal voluntary contraction (MVC)
Number of subjects: 10
Study 15937879 — intervention group
Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS) applied during muscle relaxation (control experiment)
Number of subjects: 10
Study 12598273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (5 and 10 microg)
Number of subjects: 100
Study 12598273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (2.5 and 5 microg)
Number of subjects: 100
Study 12598273 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% hyperbaric mepivacaine alone
Number of subjects: 100
Study 12598273 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% hyperbaric mepivacaine combined with intrathecal opioids
Number of subjects: 100
Study 12598273 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study 10232431 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated pulmonary stenosis (PS) children at rest
Number of subjects: 117